IP Library Granted Patent US 10,345,308
Granted Patent B2
US 10,345,308 · App. 14/521,787 · Granted Jul 9, 2019

Human serum biomarkers of prostate cancer and SARS-CoV

Inventor: Denong Wang (Menlo Park, CA)
Assignee: SRI INTERNATIONAL
G01N33/57434G01N33/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,345,308
App. No.
14/521,787
Granted
Jul 9, 2019
Kind
B2
Abstract

Anti-carbohydrate antibodies are detected by (a) contacting an array of oligomannose-serum albumin conjugates immobilized on a substrate with an antibody-containing serum sample under conditions wherein TM10 antibodies bind the oligomannose of the conjugates at at least micromolar affinity; and (b) detecting resultant binding of specific antibodies of the sample to the oligomannose of the conjugates, as indicative of the anti-carbohydrate antibodies.

Claims (11)

1. A method of determining whether a man with a prostate specific antigen (PSA) level of <10 ng/ml has prostate cancer with a Gleason grade 4 or 5, the method comprising:

(a) contacting an array of (Man 9 GlcNAc 2 Asn)-BSA conjugates immobilized on a substrate with a blood sample from the man with the PSA level of <10 ng/ml, and detecting the presence of anti-Man 9 antibodies of the sample under conditions wherein the anti-Man 9 antibodies bind the Man 9 of the (Man 9 GlcNAc 2 Asn)-BSA conjugates, wherein Man 9 is nonamannose, GlcNac is N-acetyl-D-glucosamine, Asn is asparagine and BSA is bovine serum albumin; and

(b) measuring resultant binding of the anti-Man 9 antibodies of the sample to the Man 9 of the conjugates to determine a level of anti-Man 9 antibodies in the sample,

wherein the level of the anti-Man 9 antibodies of the sample indicates that the man with the PSA level of <10 ng/ml has prostate cancer with Gleason grade 4 or 5.

2. The method of claim 1 wherein the man has prostate hyperplasia.

3. The method of claim 1 wherein the man is post-prostatectomy.

4. The method of claim 1 wherein the array further comprises asialoorosomucoid (ASOR), galacto-orosomucoid (AGOR) or orosomucoid (OR) immobilized at distinct positions on the substrate.

5. The method of claim 1 wherein the array further comprises asialoorosomucoid (ASOR), galacto-orosomucoid (AGOR) and orosomucoid (OR) immobilized at distinct positions on the substrate.

6. The method of claim 1 , wherein the substrate is an epoxy-coated glass slide and the array is a microarray.

7. The method of claim 1 , wherein the substrate is a hydrophobic polystyrene coated plastic microplate.

8. The method of claim 1 , wherein the conjugates are immobilized by coating the surface with Man 9 -BSA at 20 μg/ml in 0.1 M Sodium Bicarbonate Buffer Solution, pH 9.6 and incubating at 37° C. for 2hrs.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 31, 2014
From: SRI INTERNATIONAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034715/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2014
From: WANG, DENONG
To: SRI INTERNATIONAL
Reel/Frame 034018/0892 →
Continuity (4)
Continuation PCTUS2013037933 · Apr 24, 2013
Provisional Application 61637674 · Apr 24, 2012
Provisional Application 61759745 · Feb 1, 2013
Related Publication 20150051106A1 · Feb 19, 2015